T-DXd monotherapy (HER2+ metastatic 2L+, also HER2-low metastatic)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-TRASTUZUMAB-DERUXTECAN |
|---|
| ID | REG-TDXD-METASTATIC |
|---|---|
| Type | Regimen |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Notes
DESTINY-Breast03: superior to T-DM1 in 2L HER2+ metastatic. DESTINY-Breast04: HER2-low metastatic post-chemo (PFS + OS benefit). ILD risk dominant safety concern — boxed warning + active monitoring.
Used By
Indication
IND-BREAST-HER2-POS-MET-2L-TDXD- IND-BREAST-HER2-POS-MET-2L-TDXDIND-BREAST-HR-POS-2L-T-DXD-HER2-LOW- IND-BREAST-HR-POS-2L-T-DXD-HER2-LOWIND-BREAST-TNBC-2L-T-DXD-HER2-LOW- IND-BREAST-TNBC-2L-T-DXD-HER2-LOW